contact us krjpencn

뉴스현황

Our Events

현재 위치: > 뉴스현황 > Our Events > Medicilon appoints D...

Medicilon appoints Dr. Hong Wan as Vice President of Pharmacokinetics and Bioanalysis Department

저자:medicilon   업로드:2021-09-13  조회수:

Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of Pharmacokinetics and Bioanalysis Department.

Dr. Hong Wan, PhD in analytical chemistry from Stockholm University, Sweden, has been deeply involved in the research and development of new biomedical drugs and the CRO industry for more than 20 years. He has deep R&D strength and rich management experience in the fields of preclinical ADMET, DMPK, toxicology and biological analysis, especially in oncology, immunotherapy, diabetes, CVGI, infectious diseases and central nervous system. In addition, Dr. Wan has profound academic attainments. He is the editor-in-chief and co-editor of more than 50 publications. He has served as an honorary associate professor in the Department of Chemistry at Karlstad University in Sweden. He is an editor of ADMET/DMPK, Expert Opinion on Drug Metabolism & Toxicology. Dr. Wan is also the member of IAPC (International Association of Physical Chemists) Conference Organizing Committee and co-chair of the 9th IAPC Conference.

Prior to joining Medicilon, Dr. Wan served as the VP of pharmacokinetics and toxicology of Sironax, the head of pharmacokinetics and toxicology of Shanghai Hengrui Pharmaceutical Co., and the senior management position of Crown Biosciences and AstraZeneca (Sweden R&D Center). Dr. Wan has considerable experience and outstanding achievements in the field of preclinical DMPK and biological analysis, and has supported and completed dozens of PCC (Preclinical Candidate Compounds) evaluation and IND filing package.

Dr. Wan Hong said, "It is an honor to join Medicilon. As China's leading one-stop pre-clinical research and development platform, Medicilon has a forward-looking strategic layout and strong competitiveness. In the future, I hope that Medicilon will lead a professional team to quickly and efficiently transform the research and development results of innovative drugs, provide the best support and quality services for global new drug developers, and enable innovative drugs to benefit the patients. "

Dr. Chunlin Chen, Founder & CEO of Medicilon, said, "Dr. Wan has extensive experience in preclinical pharmacokinetics and bioanalysis, with innovative R&D thinking and excellent leadership. It is believed that the joining of Dr. Wan will greatly accelerate the pre-clinical research and development of new drugs, help Medicilon implement its growth strategy in the global market, and empower the next stage of development. "

이전:Medicilon won the Science and Technology Innovation Service Demonstration Case Award

다음에:Qing Ruan and his team examined Medicilon